Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone

Bayer

Status and phase: Completed; Phase 2

Conditions: Dialysis; Hyperphosphatemia

Treatments: Drug: Lanthanum Carbonate (BAY77-1931)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00767637

Fosrenol (Other Identifier)

11810

Details and patient eligibility

About

To measure lanthanum concentrations in bone in patients with hyperphosphatemia receiving dialysis

Enrollment: 14 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients undergoing dialysis or plan to start dialysis before the initial administration of the study medication

Exclusion criteria

• Patients with severe hypocalcemia (adjusted serum calcium level of <7.5 mg/dL)

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

14 participants in 1 patient group

Arm 1

Experimental group

Treatment:

Drug: Lanthanum Carbonate (BAY77-1931)